University Hospital RWTH Aachen

Aachen, Germany

Cancer centre – Euregional Comprehensive Cancer Center Aachen (ECCA)

Tim H. Brümmendorf

Prof. Dr. med.

Tim H. Brümmendorf

Specialized in: oncology

Curriculum vitae keyboard_arrow_down


  • Akute und chronische Leukämien
  • Maligne Lymphome
  • Molekular zielgerichtete Therapie

Wissenschaftliche Schwerpunkte

  • Telomerbiologie der Hämatopoese
  • Stammzellbiologie der Hämatopoese
  • Kinaseinhibitoren in der Therapie hämatologischer Neoplasien
  • Hypusinierung und der eukaryontische Initiationsfaktor 5a (eIF5a)


Publications keyboard_arrow_down

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killik SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G (2012) Prospective study of rabbit antithymocyte globulin and ciclosporin for aplastic anemia from the EBMT Severe Aplastic Anemia Working Party. Blood, (DOI)10.1182/blood-2012-02-407684

houry HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brummendorf TH (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapiy failure. Blood 119(15):3403-12

Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brummendorf TH (2011) Functional p53 is required for effective execution of telo-merase inhibition in BCR-ABL-positive CML cells. Exp Hematol 39(1):66-76.e1-2.ccc

Wege H, Heim D, Lütgehetmann M, Dierlamm J, Lohse AW, Brummendorf TH (2011) Forced activation of (beta)-catenin signaling is sufficient to drive transforma-tion of hTERT-immortalized human fetal hepatocytes. Mol Cancer Res 9(9):1222-31

Bartolovic K, Balabanov S, Berner B, Bühring H-J, Komor M, Becker S, Hoelzer D, Kanz L, Hofmann W-K, Brummendorf TH (2005) Clonal heterogeneity in growth kinetics of CD34+38- human cord blood cells in vitro is correlated with gene expression pattern and telomere length. Stem Cells 23(7): 946-957


The ECCA at the University Hospital Aachen under the direction of Univ.-Prof. Dr. med. Tim H. Brümmendorf offers the patients with malignant diseases a comprehensive interdisciplinary treatment. Furthermore, the involvement of the specialists from various fields in the discussions on diagnosis, therapy, prevention and rehabilitation for the patient after the operation as well as participation in the clinical researchers devoted to oncology play a key role here. 

The ECCA at the University Hospital Aachen was founded on 15th March 2010 as the multidisciplinary medical institution aimed at optimizing the care for cancer patients in the euro region. The Cancer Center consists of 9 centers and modules specializing in the treatment of cancers of certain forms and organs. 

With the aim of a better oncological care of cancer patients, all departments and institutes of the university hospital get together in the ECCA at the University Hospital Aachen and take part in the diagnosis, treatment, and research of cancer.  Due to the interdisciplinary cooperation of the members of the ECCA under the direction of Univ.-Prof. Dr. med. Tim H. Brümmendorf, the patients with oncology get the highest competence and treatment experience. 

The main aim of the ECCA at the University Hospital Aachen under the direction of Univ.-Prof. Dr. med. Tim H. Brümmendorf is to optimize and develop the contacts of various oncology specialized medical institutions in Euroregion.

Need Help?

Need Help?

Do you want the most effective treatment? We will help you to find a hospital in any country in the world specializing in your disease. Fill out the application and our specialist will contact you!

Thank you!

We received your treatment application in the best Europe clinics. Our manager will contact you within the next 24 hours.